

# Liver function monitoring scheme with Valdoxan

## ☐ Valdoxan 25 mg

- ☐ Initiation of 25mg ALT .....U/L  
AST .....U/L
- ☐ Week 3 ALT .....U/L  
AST .....U/L
- ☐ Week 6 ALT .....U/L  
AST .....U/L
- ☐ Week 12 ALT .....U/L  
AST .....U/L
- ☐ Week 24 ALT .....U/L  
AST .....U/L

Please perform a test at any time if clinically justified.

☐ In case of dose increase **at 50mg**, restart the monitoring scheme.

- ☐ Initiation of 50mg ALT .....U/L  
AST .....U/L
- ☐ Week 3 ALT .....U/L  
AST .....U/L
- ☐ Week 6 ALT .....U/L  
AST .....U/L
- ☐ Week 12 ALT .....U/L  
AST .....U/L
- ☐ Week 24 ALT .....U/L  
AST .....U/L

Please perform a test at any time if clinically justified.

Patient name: \_\_\_\_\_

Date of initiation: \_\_\_\_\_

**Symptoms or any sign of potential liver injury\***

**Serum transaminases (ALT, AST)**

ALT and/or AST  
**> 3 times the upper  
limit of normal**

ALT and/or AST  
**≤ 3 times the upper  
limit of normal**

**Normal**

**Symptoms or any sign of  
potential liver injury\***

**No symptom or sign of liver injury**  
Repeat liver function tests within 48 hours

ALT and/or AST  
**> 3 times the upper  
limit of normal**

ALT and/or AST  
**≤ 3 times the upper  
limit of normal**

 **Discontinue the treatment**

- Liver function tests  
(including transaminases)  
should be performed

 **Discontinue the treatment**

- Repeat liver function tests regularly  
until serum transaminases return to  
normal



**Continue the treatment**

- Follow the time schedule for liver monitoring tests

\* Such as dark urine, light coloured stools, yellow skin/eyes, pain in the upper right belly, sustained new-onset and unexplained fatigue